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Available online 7 October 2016Infection with one of the four dengue virus serotypes (DENV1-4) presumably leads to lifelong immunity against
the infecting serotype but not against heterotypic reinfection, resulting in a greater risk of developing Dengue
Hemorrhagic Fever/Dengue Shock Syndrome (DHF/DSS) during secondary infection. Both antibodies and T cell
responses have been implicated inDHF/DSSpathogenesis. According to the T cell-based hypothesis termed “orig-
inal antigenic sin,” secondary DENV infection is dominated by non-protective, cross-reactive T cells that elicit an
aberrant immune response. The goal of our study was to compare the roles of serotype-speciﬁc and cross-reac-
tive T cells in protection vs. pathogenesis during DENV infection in vivo. Speciﬁcally, we utilized IFN-α/βR−/−
HLA*B0702 transgenic mice in the context of peptide vaccination with relevant human CD8 T cell epitopes.
IFN-α/βR−/− HLA*B0702 transgenic mice were immunized with DENV serotype 2 (DENV2)-speciﬁc epitopes
or variants found in any of the other three serotypes (DENV1, DENV3 or DENV4), followed by challenge with
DENV. Although cross-reactive T cell responses were lower than responses elicited by serotype-speciﬁc T cells,
immunization with either serotype-speciﬁc or variant peptide epitopes enhanced viral clearance, demonstrating
that both serotype-speciﬁc and cross-reactive T cells can contribute to protection in vivo against DENV infection.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Vaccination1. Introduction
Dengue virus (DENV), a member of the Flaviviridae family, is the
most prevalent arthropod-borne virus in the world. The incidence of
DENV infections in endemic areas has increased 30-fold in the past
50 years due to demographic changes, urbanization and globalization
(Halstead, 2007; Guzman et al., 2010). New estimates report 390 mil-
lion infections per year, with 96 million being symptomatic, of which
N500,000 are reported as severe forms of dengue (Bhatt et al., 2013).
DENV is a positive sense, single-stranded RNA virus and its genome is
translated as a single poly-protein that is cleaved into three structural
(capsid (C), pre-membrane (PrM), andenvelope (E)) and sevennonstruc-
tural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) (Halstead,
2007). Infection with one of the four DENV serotypes can cause a spec-
trum of illnesses that range from dengue fever (DF) to severe forms oft enhancement; DENV, dengue
hock syndrome; HLA, human
g; IFN, interferon; NS, non-
and Immunology, 9420, Athena
. This is an open access article underdengue, previously known as dengue hemorrhagic fever/dengue shock
syndrome (DHF/DSS) (Malavige and Ogg, 2012; Jayaratne et al., 2012).
Severe dengue disease is characterized by thrombocytopenia, el-
evated hematocrit and cytokine levels, increased vascular perme-
ability, and hemorrhagic manifestations; it can ultimately lead to
death (Halstead, 2012). The mechanisms involved in the pathogene-
sis of the severe forms of dengue infection remain poorly under-
stood. Infection with one serotype confers life-long immunity
against homotypic reinfection; however, individuals re-infected
with a different serotype are prone to developing severe disease
(Halstead, 2007). Two main hypotheses implicating the host im-
mune response have been proposed to explain dengue pathogenesis
in individuals with heterotypic secondary infection. According to the
antibody dependent enhancement of infection (ADE) hypothesis,
non-neutralizing antibodies from a previous infection enhance viral
entry via Fcγ receptor (FcγR)-bearing cells upon reinfection. Studies
using mouse models of experimental DENV infection formally dem-
onstrated ADE in vivo, providing support for the ADE hypothesis
(Zellweger et al., 2010; Balsitis et al., 2010). In contrast to ADE, the
“original T cell antigenic sin” hypothesis focuses on the T cell re-
sponse (Rothman et al., 2014). It postulates that memory cross-reac-
tive T cells are preferentially activated during secondary infection,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ment of viral clearance (Mongkolsapaya et al., 2003; Bashyam et
al., 2006). To date, direct evidence in support of the original T cell an-
tigenic sin hypothesis is lacking. On the contrary, increasing number
of studies using mouse models have shown a direct contribution of T
cells in protection against DENV infection (Yauch et al., 2009; Yauch
et al., 2010; Prestwood et al., 2012; Zellweger et al., 2013; Zellweger
et al., 2014; Zellweger et al., 2015). In particular, we recently demon-
strated that CD8 T cells could directly contribute to protection
against heterotypic reinfection in mice (Zellweger et al., 2015). Con-
sistent with these mouse ﬁndings, recent studies using DENV-ex-
posed blood donors from a hyperendemic country support an HLA-
linked protective role for T cells against DENV infection in humans
(Weiskopf et al., 2013;Weiskopf et al., 2015a). Moreover, studies an-
alyzing the T cell response in general populations from two different
hyperendemic countries, Sri Lanka and Nicaragua, showed that al-
though the T cell speciﬁcity was skewed towards conserved regions,
this was not associated with impairment of the actual immune re-
sponse (Weiskopf et al., 2013; Weiskopf et al., 2015b). However,
studies examining T cell cross-reactivity in humans can be challeng-
ing to conduct, as the viral strain, sequence, or interval between in-
fections is unknown.
To perform mechanistic studies on the T cell response to DENV, a
manipulable and tractable animal model is required in which the
exact infecting viral strain, as well as the order and times of infection,
are known. Wild-type mice are highly resistant to infection with
DENV, as the virus is able to block type I Interferon (IFN) receptor
signaling in human but not murine cells (Ashour et al., 2010; Yu et
al., 2012; Aguirre et al., 2012). The antiviral IFN response must be
disrupted in mice to make them susceptible to DENV infection.
Therefore, we previously developed a model of DENV infection in IFN-
α/βR−/− mice lacking the type I IFN receptor (Perry et al., 2009;
Zellweger et al., 2010). Our group has used this mouse model to identify
protective roles for T cells in the context of various DENV infection set-
tings, including heterotypic reinfection (Yauch et al., 2009; Yauch et al.,
2010; Zellweger et al., 2010; Zellweger et al., 2015; Zellweger et al.,
2014; Zellweger et al., 2013).
To link the ﬁndings obtained from the IFN-α/βR−/− mouse model
studies to the human situation, we have also developed an IFN-α/
βR−/− HLA transgenic mouse model. This mouse model has been used
to map the DENV2- and DENV3-speciﬁc T cell response restricted by
HLA B*0702 (Weiskopf et al., 2011; Weiskopf et al., 2014), which is as-
sociated with high response frequency and magnitude and decreased
susceptibility to severe dengue disease in humans (Weiskopf et al.,
2013). Additionally, the HLA B*0702-transgenic IFN-α/βR−/− mouse
model has been validated by following observations: (i) The epitopes
identiﬁedwere also recognized by human Peripheral BloodMononucle-
ar Cells (PBMC) from DENV-exposed donors (Weiskopf et al., 2011;
Weiskopf et al., 2014); (ii) A dominance of HLA B*0702-restricted re-
sponse was detected in both mice and human peripheral blood mono-
nuclear cell (PBMC) donors (Weiskopf et al., 2013); and (iii), The
ﬁnding that CD8 T cell response targets both structural and NS proteins
in DENV3 but only NS proteins in DENV2was observed in bothmice and
humans (Weiskopf et al., 2015b; Weiskopf et al., 2015c).
In the present study, we explore the role of cross-reactive T cells in
vivo during DENV infection using the HLA-B*0702-transgenic IFN-α/
βR−/− mouse model. We show that HLA-B*0702-transgenic IFN-α/
βR−/−mice infected with DENV2mount a poly-functional antiviral im-
mune response. In particular, CD8 T cells from DENV2-infected mice
produce IFNγ, TNFα, or both cytokines when re-stimulated with
DENV2 or variant peptides from other serotypes, DENV1/3/4. Although
cross-reactive T cells elicit a weaker T cell response in vitro, immuniza-
tionwith cross-reactive peptides confers protection against DENV infec-
tion by reducing viral load. Our results do not provide support for
“original T cell antigenic sin;” instead, they demonstrate that cross-reac-
tive T cells can play a protective role against DENV infection.2. Methods
2.1. Mice and Viral Strains
HLA B*0702-transgenic IFN-α/βR−/−mice were bred at the La Jolla
Institute for Allergy and Immunology Animal Facility (La Jolla, CA). All
mouse experiments were performed following the Institutional Animal
Care and Use Committee–approved animal protocols. Age- and sex-
matched mice between 5–6 weeks of age and both male and female
mice were used in all experiments.
The mouse-adapted dengue virus 2 (DENV2), D2S10, was derived
from the clinical isolate PL046. D2S10 was obtained as described
(Shresta et al., 2006) by passaging parental virus PL046 through mice
and C6/36 mosquito cells 10 times. S221 is a triple-plaque puriﬁed
clone derived from D2S10 (Zellweger et al., 2013; Zellweger et al.,
2014). The same preparation of S221 was used for this entire project.
Mice were inoculated with a dose of 1 × 1010 genomic equivalents
(GE) S221 for challenge after immunization or 5 × 108 GE for Intracellu-
lar Cytokine Staining (ICS) and ELISPOT. For all experiments with
DENV3, EDEN3, a clinical isolate derived from the Early Dengue Infec-
tion and Outcomes Study (EDEN) (Low et al., 2006) was obtained
from Dr. Subhash Vasudevan, and mice were infected with 1 × 1010 GE.
2.2. Peptide Synthesis
All peptides were synthesized by A&A Lab LLC, San Diego. Peptides
for ELISPOT were synthesized as crudematerial andmass spectral anal-
ysis of each peptide was performed to validate the synthesis. All 9-mer
and 10-mer peptides for ﬂow cytometry and immunization were syn-
thesized and puriﬁed by reverse-phase HPLC to ≥95% purity. Peptides
were stored at−20 °C after being dissolved in DMSO and aliquoted to
avoid freeze-thaw damage.
2.3. Ex Vivo Interferon-gamma (IFN-γ) Enzyme-linked Immunosorbent
Spot (ELISPOT) Assay
CD8 T cells were isolated by magnetic bead positive selection
(Miltenyi Biotec, Germany). A total of 2 × 105 CD8 T cells were stimulat-
ed with 1 × 105 naive splenocytes as antigen presenting cells and 10 μg/
ml individual DENV2-speciﬁc peptides in 96-well ﬂat-bottom plates
(Immobilon-P; Millipore, MA) coatedwith anti–IFN-γmonoclonal anti-
body (mAb) (clone AN18; Mabtech, Sweden) in triplicate. Wells were
washed with PBS/0.05% Tween 20 after 20 h incubation at 37 °C and
then incubated with biotinylated IFN-γmAb (clone R4-6A2; Mabtech)
for 2 h. The spots were developed using Vectastain Elite ABC peroxidase
(Vector Laboratories, Burlingame, CA) and 3-amino-9-ethylcarbazole
(Sigma-Aldrich, St. Louis, MO) and counted by computer-assisted
image analysis (KS-ELISPOT reader; Zeiss, Germany).
2.4. MHC/Peptide Binding
Puriﬁcation of HLA class Imolecules and quantitative competitive in-
hibition assays to measure the binding afﬁnity of peptides to puriﬁed
MHC were performed as described elsewhere (Sidney et al., 2013).
Brieﬂy, 0.1–1 nM high-afﬁnity radiolabeled peptide was coincubated
at room temperature (RT) with 1 μM to 1 nM puriﬁedMHC in the pres-
ence of protease inhibitors and 1 μM β2-microglobulin. Following 2-
days incubation, MHC-bound radioactivity was determined by captur-
ing MHC/peptide complexes on W6/32 (anti-class I) Ab-coated
Lumitrac 600 plates (Greiner Bio-One, Germany) and measuring
bound cpm using the TopCount microscintillation counter (Packard In-
strument Company, CT), and the concentration of peptide yielding 50%
inhibition of the binding of the radiolabeled peptide was calculated.
Under the conditions used, where [label] b [MHC] and IC50 ≥ [MHC],
the measured IC50 values were reasonable approximations of true Kd
values. Each competitor peptide was tested at six different
Fig. 1. CD8 T cell reactivity against DENV2-speciﬁc HLA-B*0702 restricted epitopes.
Previously identiﬁed DENV2 speciﬁc epitopes were tested in an IFNγ ELISPOT assay to
determine response hierarchies after infection with DENV2. ELISPOT was performed
using CD8 T cells isolated from HLA-B*0702-transgenic type I IFN receptor knockout
C57BL/6 mice (IFN-α/βR−/−) seven days after intravenous infection with 5 × 108 GE of
DENV2. CD8 T cells were stimulated with naive splenocytes as antigen presenting cells
(APC) and 10 μg/ml of individual peptides. The data are expressed as the mean number
of SFC per 106 CD8 T cells. Peptides were tested in triplicates in ﬁve independent
experiments (total n= 20 mice). Average responses between all experiments are shown
and the error bars are presented in SEM. Peptide inducing robust T cell responses (N800
SFC/106 CD8 T cells) are represented with blue bars.
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independent experiments. As a positive control, the unlabeled version
of the radiolabeled probe was also tested in each experiment.
2.5. Flow Cytometric Analyses
Mice were sacriﬁced by isoﬂurane inhalation and spleens were col-
lected in 10% FBS media. For ICS, splenocytes were counted after red
blood cell lysis and were plated as 2 × 106 splenocytes/well in in 96-
well U-bottom plates. Cells were stimulated with individual or pooled
DENV2 peptides (5 μg/ml of each peptide) or their respective variants
for 6 h, in the presence of Brefeldin A (GolgiPlug; BD Biosciences) and
anti-CD107a PE (clone 1D4B, eBioscience) during the 4 last hours. Dif-
ferent concentrations of pooled peptides (5, 0.5, 0.05 and 0.005 μg/ml)
were tested in T cell avidity assays.
Cellswerewashed and labeledwith anti-CD3 PerCpCy 5.5 (Clone 145-
2C11, TONBO), anti-CD8 PE-Cy7 (clone 53-67, BD biosciences), anti-CD44
eFluor 450 (clone IM7, eBioscience), anti-CD62L APC eFluor 780 (clone
Mel-14, eBioscience). Then, cells were ﬁxed and permeabilized using the
BD Cytoﬁx/Cytoperm Kit, and stained with a combination of anti-IFNγ
FITC (clone XMG 1.2, TONBO) and anti-TNFα APC (clone MP6-XT22,
eBioscience). Samples were read on an LSR II (BD Biosciences) and were
analyzed using FlowJo software X 10.0.7 (Tree Star, Ashland, OR).
2.6. Peptide Immunization
HLA B*0702-transgenic IFN-α/βR−/−mice were immunized subcu-
taneously (s.c)with a combination of 100 μg of HCV-core helper peptide
(I-Ab restricted, TPPAYRRPPNAPIL) and 50 μg of each ﬁve DENV2 pep-
tides NS31682–1690, NS31700–1709, NS32070–2078, NS4B2280–2289, NS52885–
2894 or their corresponding variant peptides fromDENV1/3/4 emulsiﬁed
in Complete Freund Adjuvant (CFA) (Difco, Detroit, MI). Mock-immu-
nized mice received a combined injection of helper peptide and
DMSO. Following 21 days post-priming, mice were boosted with the
samemixture as noted above emulsiﬁed in Incomplete FreundAdjuvant
(IFA) and challenged nine days later with 1 × 1010 GE of DENV2 strain
S221 or 1 × 1010 GE of DENV3 strain EDEN3 intravenously (i.v.). Three
days post-challenge, organs were harvested after PBS perfusion and
blood was collected by cardiac puncture. RNA was isolated, and
DENV2 orDENV3 viral RNA levelsweremeasured by real-timeqRT-PCR.
2.7. Statistical Analyses
All data were analyzed with Prism software version 5.0 (GraphPad
Software, Inc., San Diego, CA) and expressed as mean± SEM. Statistical
signiﬁcance was determined using unpaired t-test withWelch's correc-
tion for the viral RNA levels. Two ways ANOVA or Kruskal Wallis tests
were used to compare N2 groups. p b 0.05was considered as signiﬁcant.
3. Results
3.1. Selection of Immunodominant T Cell Response Induced by DENV2
Infection
To investigate the immunogenicity and immunodominance of class I
restricted CD8 T cells of human relevance, HLA B*0702-transgenic IFN-
α/βR−/−mice were used. This particular HLA transgenic mouse model
was selected because our study using human PBMC from DENV-ex-
posed blood donors revealed that the HLA B*0702 allele is associated
with mild disease and T cell responses high in frequency and magni-
tude; in contrast, HLA alleles such as A*0101 and A*2401 are associated
with severe dengue disease and weak DENV-speciﬁc T cell response
(Weiskopf et al., 2013). Based on our published study that identiﬁed
DENV 2 speciﬁc epitopes in HLA B*0702-restricted IFN-α/βR−/− mice
(Weiskopf et al., 2011), we ﬁrst evaluated the ability of the 12 DENV2
epitopes identiﬁed in that study to induce a strong T cell response inHLA-B*0702-transgenic IFN-α/βR−/−mice. The capacity of each of the
12 DENV2 peptides to induce a T cell response was evaluated by IFNγ
ELISPOT (Fig. 1). We selected 5 peptides that elicited high magnitude
T cell responses (N800 SFC/106 CD8 T cells: NS31682–1690 (1050 ± 405
SFC/106), NS31700–1709 (1166 ± 351 SFC/106), NS32070–2078 (1601 ±
179 SFC/106), NS4B2280–2289 (1061.33 ± 404.84 SFC/106) and NS52885–
2894 (891.00 ± 331.63 SFC/106)). This immunodominance pattern is in
accordance with published studies demonstrating that DENV NS3,
NS4B, and NS5 are the main targets of the CD8 T cell response
(Duangchinda et al., 2010; Weiskopf et al., 2013).
We compared the amino acid sequence of DENV2 to the sequence at
the same position in other serotypes (DENV1/3/4) for each of the 5
immunodominant epitopes. The sequence and the position of each epi-
tope in the polyprotein are summarized in Table 1. DENV2 peptides can
be characterized into two groups in terms of their pattern of sequence
homology: conserved or DENV2-speciﬁc. Three of the 5DENV2 peptides
were conserved—i.e. the same peptide sequence existed in 2 ormore se-
rotypes. The other 2 peptides were DENV2-speciﬁc—i.e. at least one
amino acid of the DENV2 peptide sequence was different in DENV1,
DENV3, and DENV4 (DENV1/3/4). We refer to these alternative se-
quences with at least one amino acid difference from DENV2 as cross-
reactive variants. For example, NS31682–1690 is conserved (same amino
acid sequence) in DENV2, DENV1, and DENV3, and the corresponding
peptide in DENV4 is a cross-reactive variant with a different amino
acid in two positions. NS32070–2078 is DENV2-speciﬁc, as the DENV2 se-
quence is different than DENV1, DENV3, and DENV4. The homology
seen in conserved peptides is due to the high amino acid conservation
between the four DENV serotypes (67–75%) (Kuno et al., 1998). No var-
iation of the T cell response was observed regarding the pattern of se-
quence homology in DENV2 peptides (speciﬁc and conserved peptides).
3.2. TheMagnitude of the Cross-reactive CD8 T Cell Response is Either Equal
or Lower Magnitude Than DENV2 Serotype-speciﬁc T Cell Response
We next compared the CD8 T cell response induced by variant pep-
tides relative to the 5 immunodominant epitopes in an IFNγ ELISPOT
analysis (Fig. 2 and Table 1). The DENV2-exposed T cell responses varied
in response to variant peptides (Fig. 2). The T cell response to variant
Table 1
Characterization of DENV2 peptides and their corresponding variant peptides from other serotypes.
The position, sequence, length, and the serotype of each of ﬁve peptides inducing a strong T cell response are represented. The changed amino acid in each variant peptide is indicated in
red. The half maximal inhibitory concentration IC50 (nM) deﬁned the binding afﬁnity for the MHC of each peptide. The magnitude of T cell response was assessed using ELISPOT IFNγ in
SFC/106 of CD8 T cells. All of the data are expressed in standard error of mean (SEM). The percentage of IFNγ production upon stimulation by variant peptides in comparison to DENV2
peptides are represented in blue.
Protein Position Sequence Length Serotype IC50 nM SFC/10
6 CD8+ T cells % of CD8+ T cell response to DENV2
NS3 1682–1690 LPAIVREAI 9 DENV2/1/3 2.41 1050 ± 181.1 100
LPSIVREAL 9 DENV4 0.31 998.3 ± 162.4 96.5
NS3 1700–1709 APTRVVAAEM 10 DENV2/3/4 2.94 1167 ± 157.1 100
APTRVVASEM 10 DENV1 2.96 835.3 ± 70.64 73.94
NS3 2070–2078 KPRWLDARI 9 DENV2 1.78 1602 ± 80.19 100
RPKWLDARV 9 DENV4 1.77 303.7 ± 82.78 33.19
NS4B 2280–2289 RPASAWTLYA 10 DENV2/1/4 3.29 1061 ± 181.1 100
HPASAWTLYA 10 DENV1/3 6.15 387.3 ± 196.8 40.44
NS5 2885–2894 TPRMCTREEF 10 DENV2 3.11 891 ± 148.3 100
KPRLCTREEF 10 DENV3 2.07 583 ± 198.1 59.44
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the DENV4 NS31682–1690) to low responses with only 33.19% of the
DENV2 magnitude for DENV4 epitope NS32070–2078 (Table 1). These re-
sults indicate the presence of cross-reactive T cells after DENV2 infection.
In terms of cross-reactivity, two variant peptides, NS32070–2078 and
NS4B2280–2289 with 33.19 and 40% of CD8 T cell response, respectively,
elicited notably lower magnitude T cell responses compared to their
corresponding DENV2 sequence. Both the number (1, 2, or 3) and posi-
tion (ﬁrst, last, or middle position in peptide) of the amino acid changes
did not seem to inﬂuence the magnitude of the CD8 T cell response. For
instance, the cross-reactive variant peptide that best matched the
DENV2 peptide in terms of the magnitude of the T cell response
(NS31682–1690) differs in two amino acids, whereas the NS4B2280–2289
epitope in DENV1 or DENV3 that differs in only one amino acid from
DENV2 elicited 40% of DENV2-speciﬁc T cell response.
To determine if binding efﬁciency could affect the T cell response,we
performed HLA binding assays with each peptide (speciﬁc, conserved,
or variant, Table 1) as previously described (Sidney et al., 2013). All pep-
tides showed a high afﬁnity to the MHC molecule, as indicated by an
IC50 ≤ 10 nM independent of the number of amino acid changes. Thus,
binding efﬁciency is not likely responsible for the signiﬁcant reductionNS
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Fig. 2. CD8 T cells response after stimulation by DENV2-speciﬁc or DENV1/3/4 variant
peptides. IFNγ ELISPOT was performed using CD8 T cells isolated from HLA-B*0702-
transgenic IFN-α/βR−/− seven days after intravenous infection with 5 × 108 GE of
DENV2. CD8 T cells were stimulated with naive splenocytes as APCs and 10 μg/ml of
individual peptide. All ﬁve DENV2-speciﬁc peptides that induced strong T cell responses
are shown in blue (DENV2) and their corresponding variant peptides from other
serotypes in white (DENV1/3/4). The data are expressed as the mean number of SFC per
106 CD8 T cells and correspond to an average of ﬁve independent experiments
performed in triplicate. The error bars are presented in SEM. Two way ANOVA, multiple
comparisons was used for statistical test, * b 0.05 and ****p b 0.0001.in some of the cross-reactive T cell responses. In particular, the binding
afﬁnities of the NS32070–2078 and NS4B2280–2289 variant epitopes were
1.77 and 6.15 nM, respectively, which were equal to or comparable to
the value of their DENV2 counterparts, albeit the cross-reactive and
DENV2-speciﬁc T cell magnitudes were different.
3.3. The Cross-reactive CD8 T Cell Response Is Multifunctional in Terms of
Cytokine Production
To assess the multi-functionality of the cross-reactive vs. DENV2-
speciﬁc CD8 T cells, we performed intracellular cytokine staining (ICS).
Splenocytes were isolated from HLA-B*0702-transgenic IFN-α/βR−/−
mice infected with 5 × 108 GE of DENV2 (S221 strain) and stimulated
ex vivo with single or pooled peptides (Corresponding to a mix of all
ﬁve immunodominant epitopes for DENV2 or all ﬁve peptides used as
variant in other serotypes) in the presence of Brefeldin A (BFA) and
CD107a for 4 h. Cells were stained for intracellular cytokines IFNγ and
TNFα. All infected mice had twice as many CD8 T cells in spleens com-
pared to uninfected control animals (data not shown), indicating an ef-
ﬁcient infection.
The percentage of cells producing IFNγ and TNFα upon stimulation
with DENV2 speciﬁc peptides or their corresponding variants from
DENV1/3/4 is represented in Fig. 3a. The frequencies of the single posi-
tive, DENV2-exposed CD8 T cells were higher after stimulation with the
DENV2 peptide pool (0.74 ± 0.12% and 0.46 ± 0.06%, respectively, for
IFNγ and TNFα) than the variant peptide pool (0.30 ± 0.05% and
0.18 ± 0.02%, respectively, for IFNγ and TNFα), but this difference
was not signiﬁcant. However, the percentage of double positive cells
(IFNγ+TNFα+) in response to the DENV2 peptide pool (0.30 ±
0.05%) was signiﬁcantly higher than to variant peptide pool (0.08 ±
0.01%), revealing that the DENV2-exposed CD8+ T cell population
contained a signiﬁcantly higher frequency of IFNγ+TNFα+ double pos-
itive cells following stimulation with pooled DENV2 peptides than
cross-reactive peptides (Fig. 3a).
In terms of the cytokine proﬁle, DENV2-exposed CD8 T cells elicited a
similar pattern of cytokines in thepresence of DENV2 or DENV1/3/4 pep-
tides (Fig. 3b). The pie-chart is divided into three parts showing that the
DENV2-exposed CD8 T cell population included 40.9% of IFNγ+ cells,
31.9% of TNFα+ cells, and 27.6% of double positive cells after stimulation
with the DENV2 peptide pool, and 30.3% of IFNγ+ cells, 34.0% of TNFα+
cells, and 35.8% of double positive cells after stimulationwith the variant
peptide pool (Fig. 3b). Further analysis using individual peptide instead
of peptide pools revealed that the cytokine proﬁle of DENV2-exposed
CD8 T cells upon stimulation with each individual DENV2 peptide pre-
sented the same pattern represented by an equal distribution of IFNγ+,
TNFα+, and IFNγ+TNFα+ cells (Fig. 3c, left panel). A similar pattern
has been identiﬁed for three of the ﬁve individual variant peptides (Fig.
3c right panel, NS31682–1690, NS31700–1709, NS52885–2894 epitopes). Two
Fig. 3. Functional phenotype of serotype-speciﬁc vs. cross-reactive CD8 T cells. Mice were
infectedwith 5 × 108 GE of DENV2 (Infected) or injectedwith 10% FBS-PBS (naïve). Seven
days later, spleens were harvested and ICS was performed with individual or previously
selected pooled peptides. (a) The frequency of CD8 T cells expressing IFNγ (Yellow),
TNFα (Salmon) or IFNγTNFα (Blue) in infected mice without the background produced
by naïve mice. (b) The cytokine proﬁle of CD8 T cells in response to DENV2 or DENV1/3/
4 peptide stimulation, as illustrated in pie-charts. These pie-charts show the percentage
of IFNγ (Yellow), TNFα (Salmon) or IFNγTNFα (Blue) frequencies compared to whole
cytokine production. (c) The cytokine proﬁle induced by stimulation with individual
peptide. (d) The frequency of double positive cells for IFNγ and CD107a produced by
splenocytes from infected (Black bar) or naïve (White bar) mice. Experiments were
performed twice with a total number of 11 infected mice for DENV2 stimulation, 12
infected mice for DENV1/3/4 stimulation, and 9 naïve mice. Each independent
experiment showed similar results. The error bars are represented in SEM. Kruskal-
Wallis multiple comparisons was used for statistical test. * b 0.05.
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favor of IFNγ production: NS32070–2078 and NS4B2280–2289 with 67.57%
and 96.49%, respectively (Fig. 3c). However, T cells stimulated by pooled
peptides (DENV2 or DENV1/3/4) reveal the same pattern. Over all, these
results show that no speciﬁc cytokine patternwas observed in DENV1/3/
4 cross-reactive vs. DENV2 serotype-speciﬁc CD8 T cell responses.
CD107a is present on the inner membrane of vesicles containing
perforin and granzymes, so positive staining deﬁnes degranulation of
activated T cells (Alter et al., 2004). In all our experiments, N95% of
IFNγ producing cells are CD107a positive cells (data not shown).
CD107a, combined with IFNγ, determine CD8 T cells capable of elimi-
nating virus-infected cells (Fig. 3d). DENV2 peptides induced a higher
percentage of CD107a+IFNγ+ CD8 T cells (0.27 ± 0.09%) compared to
DENV1/3/4 peptides (0.06 ± 0.01%).
Based on studies suggesting that cross-reactive T cells with low af-
ﬁnity are activated during secondary DENV infection in humans
(Mongkolsapaya et al., 2003; Rothman et al., 2014; Screaton et al.,
2015), we next determined the functional avidity of DENV2-exposed
CD8 T cells in response to cross-reactive peptides. ICS was performed
to measure IFNγ production by DENV2-exposed T cells upon stimula-
tion with different concentrations of DENV2 or variant peptide pool. A
response was considered positive if IFNγ production was signiﬁcantly
higher than measured in background experiments (Fig. 4. naïve mice,
white bars). The DENV2 peptide pool was able to induce production of
IFNγ at lower concentrations (0.5 and 0.05 μg/ml, only signiﬁcantly
higher for 0.5 μg/ml) than the variant peptide pool (Fig. 4), indicating
that DENV2-exposed T cells have a lower avidity response upon stimu-
lation with cross-reactive peptides than with DENV2 peptides.
3.4. Immunization With DENV1/3/4 Variant Peptides Can Protect Against
DENV2 or DENV3 Infection in HLA-B*0702-Transgenic IFN-α/βR−/−Mice
To investigatewhether variant peptides can contribute to protection
against DENV infection, our previously published vaccination strategy
was adopted (Yauch et al., 2009; Yauch et al., 2010). One group of
HLA-B*0702-transgenic IFN-α/βR−/− transgenic mice received an in-
jection (s.c.) of the ﬁve DENV2 peptide cocktail in Complete Freund Ad-
juvant (CFA), while the other experimental groupwas administered the
corresponding variant peptide cocktail. A control group was included in
which mice were treated with only the helper peptide and DMSO.
Twenty-one days after the ﬁrst immunization, mice were boosted
with the same peptides in Incomplete Freund Adjuvant (IFA). Nine
days after the boost, mice were challenged with 1 × 1010 GE of DENV2
(S221 strain), followed by quantiﬁcation of DENV2 RNA levels in tissues
by qRT-PCR on day 3 after challenge.Mice immunizedwithDENV2pep-
tides or DENV1/3/4 variant peptides had signiﬁcantly lower levels of
DENV2RNA in serum, spleen, and liver as compared to themock-immu-
nized group (Fig. 5a). These results imply that DENV1/3/4-cross-reac-
tive T cells can contribute to protection against DENV2 infection. To
validate and extend these results to protection against another DENV
serotype, we used the same immunization protocol described above
and challenged mice with DENV3. DENV3 RNA levels in the serum of
DENV2- or DENV1/3/4-immunized mice were lower as compared to
mock-immunized mice (Fig. 5b). DENV3 RNA levels in the liver and
spleen of the peptide-immunized groups trended to decrease relative
to mock-immunized mice, although no signiﬁcant difference was ob-
served between peptide-immunized and mock-immunized animals.
Taken together, these results demonstrate that DENV serotype-cross-
reactive CD8 T cells can mediate protection.
3.5. Cross-reactive T Cells Elicit a Polyfunctional T Cell Response In Vivo
To conﬁrm that cross-reactive T cells were responsible for protection
against DENV2 challenge in the peptide-immunizedmice, we evaluated
the CD8 T cell response in the immunized mice via ICS just prior to and
3 days after viral challenge. CD44 and CD62L expression was used todiscriminate the effector memory subset of CD8 T cells, and antigen-
speciﬁc cells were assessed based on IFNγ expression by CD44+
CD62L− effector memory subset (Fig. 6a).
Just prior to viral challenge on day 9 after the boost,mice immunized
with DENV2 peptides had a higher percentage of IFNγ+ effector mem-
ory CD8 T cells (0.78 ± 0.11%) than mice that were mock-immunized
(0.19 ± 0.07%) or immunized with variant peptides (0.23 ± 0.05%)
upon stimulation with DENV2 peptides (Fig. 6b, left panel). In contrast,
no difference was observed in the frequency of IFNγ-producing central
memory subsets (identiﬁed based the expression of CD44 and CD62L)
in peptide-immunized vs. mock-immunized mice. Approximately
0.2 ± 0.04%, 0.21 ± 0.05%, and 0.15 ± 0.04%, respectively, were IFNγ-
producing central memory CD8 T cells in the mock-, DENV2 peptide-,
and DENV1/3/4 peptide-immunized mice before challenge (Fig. 6c, left
panel). After challenge, the frequency of IFNγ-producing central mem-
ory CD8 T cells was similar to that obtained before challenge (Fig. 6c,
right panel).
Mice immunized with DENV2 peptides also tended to have higher
frequency of potentially cytotoxic (i.e. CD107a+IFNγ+) CD8 T cells
than the other two groups of animals, albeit this difference was not sig-
niﬁcant (Fig. 6d, left panel). Three days after DENV2 challenge of the im-
munized mice, mice immunized with DENV2 peptides or variant
peptides contained signiﬁcantly higher frequency of IFNγ+ effector
memory CD8 T cells upon stimulation with DENV2 peptides (Fig. 6b,
right panel). Both groups of peptide-immunized mice also seemed to
contain higher percentages of potentially cytotoxic CD107a+IFNγ+
Fig. 3 (continued).
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together, results shown in Figs. 5 and 6 demonstrate the presence of
multifunctional DENV serotype-cross-reactive T cells that can mediate
viral clearance.4. Discussion
Epidemiological studies have highlighted an increase of severe dis-
ease manifestations (DHF/DSS) during secondary infections with
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290 A. Elong Ngono et al. / EBioMedicine 13 (2016) 284–293different DENV serotype (Halstead, 2007). To explain this epidemiolog-
ical observation, two dominant hypotheses have been postulated: ADE
and T cell original antigenic sin. The relevance of ADE to DHF/DSS path-
ogenesis had been controversial until the demonstration of ADE in vivo
in 2010,when our laboratory and another group independently demon-
strated that subneutralizing levels of antibody can turn a mild illness
into a lethal disease in mice lacking IFN-α/β receptor alone or both
IFN-α/β andγ receptors (Zellweger et al., 2010; Balsitis et al., 2010). Un-
like wild-type mice, the IFN receptor-deﬁcient mice support high levels
of DENV replication and in the ADEmodel of infection, develop signs of
disease that mimic DHF/DSS in humans (Zellweger et al., 2010). InFig. 6. CD8 T cell response in mice immunized with DENV2 or DENV1/3/4 variant peptides bef
(DENV2) or their corresponding variants (DENV1/3/4) and were boosted with the same mixt
stimulated with either individual or pooled DENV2 peptides in presence of Brefeldin A and C
IFNγ positive CD8 T cells is illustrated. (b) The frequencies of effector memory CD8 T cells pro
days after challenge with 1 × 1010 GE DENV2 (right panel) are shown. (c) The frequencies of
DENV2 are represented. (d) CD107a and IFNγ double expression in mock (white), DENV2
challenge (right panel) is shown. The results were pooled from two independent experiment
data are expressed in standard error of mean (SEM). Kruskal-Wallis multiple comparisons wascontrast, no study to date has provided direct evidence in support of
the original T cell antigenic sin hypothesis. As a step towards addressing
this hypothesis, in this study, we investigated the contribution of DENV
serotype-speciﬁc vs. cross-reactive CD8 T cells to protection against
DENV infection using an HLA transgenic mouse model of human rele-
vance. Our results demonstrated that both serotype-speciﬁc and cross-
reactive CD8 T cells could reduce DENV burden in tissues, providing
no direct evidence for the original T cell antigenic sin hypothesis. In-
stead, our ﬁndings support recent data implicating HLA-linked protec-
tive role for CD8 T cells against DENV infection in humans (Weiskopf
et al., 2013).ore and after DENV2 challenge. Mice were immunized with a mix of ﬁve DENV2 peptides
ure 21 days later. Nine days after boosting, spleens were harvested and splenocytes were
D107a. (a) The gating strategy to select effector memory (EM) or central memory (CM)
ducing IFNγ 30 days after immunization (left panel) and the frequencies obtained three
central memory cells producing IFNγ in all three groups before and after challenge with
(black), and DENV1/3/4 (grey) peptide-immunized mice before (left panel) and after
s with n = 7 mice/group before challenge and n = 8 mice per group after challenge. All
used as a statistical test. * b 0.05, ** b 0.005.
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292 A. Elong Ngono et al. / EBioMedicine 13 (2016) 284–293HLA-transgenic mice are widely used to model the human T cell re-
sponse in mice. We focused the present study on the HLA B*0702 allele,
which is associated with strong T cell response in terms of magnitude
and breath (Weiskopf et al., 2013), thereby allowing us to test the role
of multiple cross-reactive epitopes using our HLA B*0702-transgenic
IFN-α/βR−/−mouse model of DENV2 infection. Studies with DENV-ex-
posed human PBMC have shown that serotype cross-reactive T cells can
be preferentially activated and can exhibit an altered phenotype in
terms of cytokine production, degranulation, and avidity (Mangada
and Rothman, 2005; Mongkolsapaya et al., 2003; Mongkolsapaya et
al., 2006). In particular, Rothman and colleagues reported a lower afﬁn-
ity of CD8 T cells for the sequence from another serotype during second-
ary infection and preferential cytokine production in favor of TNFα by
cross-reactive CD8 T cells (Bashyam et al., 2006). Screaton and col-
leagues similarly reported activation of cross-reactive CD8 T cells with
low avidity in DHF/DSS patients (Mongkolsapaya et al., 2003). Based
on these ﬁndings, cross-reactive T cells have been hypothesized to
play a pathogenic role during DENV infection. Our results, however,
show that cross-reactive T cells do not appear to exhibit an altered cyto-
kine proﬁle and that cross-reactive T cells can decrease viral burden in
tissues despite having lower magnitude and avidity than serotype-spe-
ciﬁc T cells. Our ﬁndings are consistent with an increasing number of
new studies implicating a protective role for T cells during DENV infec-
tion in humans. In addition to our studies revealing an association be-
tween HLA-linked T cell responses and disease susceptibility
(Weiskopf et al., 2013;Weiskopf et al., 2015b), an earlier study by a dif-
ferent group observed that the breadth andmagnitude of the CD8 T cell
response during secondary DENV infection was not signiﬁcantly associ-
ated with disease severity (Simmons et al., 2005). Most recently, anoth-
er group reported that the expansion of effector memory CD8 T cells
during acute DENV infection correlated with reduced viremia (de
Matos et al., 2015).
Using H-2b mice (i.e. non HLA-transgenic) lacking IFN-α/β receptor
alone or both IFN-α/β and γ receptors, we have previously demonstrat-
ed that CD8 T cells can play a critical role in protection against DENV in
the context of primary infection (Yauch et al., 2009; Prestwood et al.,
2012), vaccination (Zellweger et al., 2013), heterotypic secondary infec-
tion (Zellweger et al., 2015), and ADE (Zellweger et al., 2014). The pres-
ent study with HLA transgenic mice highlights the role of serotype-
speciﬁc and cross-reactive CD8 T cells in protection against DENV
infection in the context of epitopes that are recognized by humans. Col-
lectively, our studies with mouse models and new studies supporting a
protective role for CD8T cells against DENV infection in individuals from
endemic countries imply that a dengue vaccine should elicit a robust,
long-lasting CD8 T cell response. Based on the present results, this opti-
mal CD8 T cell response should ideally include a combination of each of
the four DENV serotype-speciﬁc, conserved (i.e. identical in more than
one serotype), and cross-reactive CD8 T cells that are polyfunctional.
However based on thepresent study,we cannot reject thepossibility
that cross-reactive T cells are pathogenic at late stages of DHF/DSS de-
velopment. For instance, pathogenic T cells may be a consequence of
DHF/DSS rather than a cause. In this scenario, cross-reactive T cells are
protective in most secondary infection cases but some unknown factors
induces an irregularity in the environment that switch the function of T
cells from protective to pathogenic in DHF/DSS patients. Studies investi-
gating the role of cross-reactive CD8 T cells in the context of severe vs.
mild disease using IFN-α/βR−/−mice that are transgenic for particular
alleles associated with strong vs. weak T cell responses may reveal the
potentially pathogenic role of cross-reactive T cells during DENV
infection.
Consistent with our overall assertion that serotype-speciﬁc, con-
served, and cross-reactive T cells all can contribute to protection against
DENV infection, phase 2b and 3 trials of Sanoﬁ's DENV-yellow fever
virus (YFV) chimeric vaccine showed limited efﬁcacy depending on
the serotype and host immune status (Guy et al., 2015; Guy and
Jackson, 2016; Hadinegoro et al., 2015; Halstead and Russell, 2016). Inparticular, the Sanoﬁ vaccine contains YFV but not DENV NS proteins,
which are the major targets of the anti-DENV CD8 T cell response
(Weiskopf et al., 2013), suggesting that the absence of the vaccine-in-
duced DENV-speciﬁc CD8 T cell response may be responsible for the
lack of robust protection observed in the Sanoﬁ clinical trials. In compar-
ison with the Sanoﬁ vaccine, the other two leading vaccine candidates
developed by NIH and Takeda are also live-attenuated viruses, but are
not chimeric of two different ﬂaviviruses. The NIH and Takeda vaccine
candidates represent only DENV, and thus contain DENV NS proteins.
However, the NIH tetravalent vaccine formulation contains NS proteins
from 3 DENV serotypes, while the Takeda tetravalent formulation con-
sists of NS proteins from only 1 DENV serotype. Phase 1 trials have
shown that both the NIH and Takeda vaccine can induce DENV-speciﬁc
T cell responses (Weiskopf et al., 2014; Chu et al., 2015). While the NIH
vaccine-induced CD8 T response in phase 1 participants focused on con-
served epitopes (i.e. identical in N1 serotype) (Weiskopf et al., 2014),
the speciﬁcity of the Takeda vaccine-induced CD8 T cell response is as
yet to be fully deﬁned and may differ from the NIH vaccine by targeting
DENV2 serotype-speciﬁc, conserved, and cross-reactive epitopes. Our
ﬁnding that cross-reactive T cells with even low avidity and magnitude
can limit viral burden in mice imply that both NIH and Takeda vaccines
may show good efﬁcacy in phase 2 and 3 trials. In summary, our results
emphasize that a DENV vaccine should elicit not only Ab but also CD8 T
cell responses to maximize efﬁcacy.5. Conclusion
The T cell response to DENV has been implicated to play a dual role
in both protection and pathogenesis. In particular, serotype-cross-reac-
tive T cells have been hypothesized to contribute to DENV pathogenesis.
However, no study to date has provided direct evidence supporting a
pathogenic role for T cells during DENV infection. To address the poten-
tially pathogenic role of DENV antigen-speciﬁc T cells, the present study
evaluated the role of serotype-speciﬁc vs. cross-reactive CD8T cellswith
known antigen speciﬁcity using aHLA transgenicmousemodel of DENV
infection and a peptide immunization setting. The results show that both
serotype-speciﬁc and cross-reactive CD8 T cells can contribute to protec-
tion against DENV challenge, consistent with emerging literature impli-
cating an important role for T cells in protection against DENV infection.Conﬂict of Interest Statement
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